San Antonio, Texas (ots/PRNewswire) - New data presented today at the San Antonio Breast Cancer Symposium (SABCS) show that adding Xeloda (capecitabine) to the current gold standard combination of Herceptin (trastuzumab) and docetaxel allows patients with advanced HER2-positive breast cancer to live, on average 5 ...
Basel, Switzerland (ots/PRNewswire) - - Physicians Will be Able to Prescribe MabThera With Their Preferred Chemotherapy Regimen as Initial Treatment Roche announced today that the European Union's Committee on Human Medical Products (CHMP) has given a positive recommendation for extension of the MabThera ...
Basel, Switzerland (ots/PRNewswire) - Roche has received positive recommendations for the Marketing Authorisation extensions for both its anti-angiogenic agent Avastin (bevacizumab) and oral chemotherapy Xeloda (capecitabine) from the European Committee for Medicinal Products for Human Use (CHMP). The ...
Baar (ots) - "The Albanian Council of Ministers has approved Decision No. 796 regarding the approval of production sharing for exploration, development and production of hydrocarbons on onshore Albania, in Blocks A-B and D-E, between the Ministry of Economy, Trade and Energy, represented by the National Agency of ...
Malvern, Pennsylvania (ots/PRNewswire) - - Solstice Neurosciences, Inc. Launches a Self-Guided Lesson as Prep for In-Person Workshops In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia (CD), Solstice Neurosciences, Inc. (Solstice) has created ...
Basel, Switzerland (ots/PRNewswire) - - Higher Response Rates Seen in Untreated and Relapsed CLL Patients For non-US media only Abstract Number: 626 Abstract Number: 752 Early results from two phase II trials tracking the outcome of patients with chronic lymphocytic leukaemia (CLL) who were treated with the innovative cancer therapy MabThera ...
Calgary, Canada (ots/PRNewswire) - - New Class of ApoA-I/HDL Drugs to Reverse Atherosclerosis Enters the Clinic Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small ...
Basel, Switzerland (ots/PRNewswire) - - Phase II Results Suggest Avastin Can be Used in Curative Setting Date Experts attending the 30th San Antonio Breast Cancer Symposium (SABCS) December 13-16, will be amongst the first to hear new data that highlight further advances in the treatment of breast ...
Copenhagen (ots/PRNewswire) - - Attention Medical Trade Press Only - Further Study Demonstrates Efficacy and Tolerability of Escitalopram in Premenstrual Dysphoric Disorder New data released today reinforces the superiority of escitalopram compared to duloxetine in the acute treatment of depression ...
Toronto (ots/PRNewswire) - "Governments need to recognize the rights and needs of people with disabilities," says Prof. Allen Foster, President of CBM on the International Day of Disabled Persons. Millennium Development Goals set out by the United Nations will not be achieved without the inclusion of the disabled in development programming states Foster. CBM is a leading advocate for the human rights of ...
Calgary, Canada, November 29 (ots/PRNewswire) - - ApoA-I Technology is Recognized for its Ability to Transform the Treatment of Cardiovascular Disease Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that the World Economic Forum has selected Resverlogix as a winner of the very prestigious Technology Pioneer Award in recognition of ...
Leipzig, Germany, November 29 (ots/PRNewswire) - - Ophthalmic Clinic in Germany First in Europe To Treat Patients With New Focused Radiation Therapy NeoVista, Inc. announced today that the first European patient has been treated in the company's pivotal global clinical trial for its novel beta radiation epiretinal therapy for the wet form of age-related ...
Collegeville, Pennsylvania, November 26 (ots/PRNewswire) - - TORISEL Extends Median Overall Survival vs. Interferon-Alpha Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved TORISEL(TM) (temsirolimus) for the first-line treatment of patients ...
Toronto, November 22 (ots/PRNewswire) - "CBM urgently needs help for the most vulnerable people affected by the recent flooding in Bangladesh," says Prof. Allen Foster President of CBM. The latest report says the death toll in the fiercest cyclone to hit Bangladesh's southern and southwestern coastal area in over 130 years has climbed to over 2,300. "Our staff and partners on the ground are reporting that many people with disabilities living in poverty are ...
Basel, Switzerland, November 20 (ots/PRNewswire) - - Annals of Oncology Paper Suggests That Oral Agents Such as Xeloda, Which are Proven to be Equally Effective and Have a Tolerable Side Effect Profile, Should Replace Traditional Intravenous Chemotherapy A review paper in Annals of Oncology now ...
Amsterdam, November 19 (ots/PRNewswire) - Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment to treat new patients and is expected to complete ...
Basel, Switzerland, November 16 (ots/PRNewswire) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Avastin (bevacizumab) for ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 09.11.2007 Pfaeffikon SZ, 9 November 2007 --- The Board of Directors of shaPE Capital AG has decided to simplify its management structure by replacing the full-time CEO position with a part-time Company Secretary function. In this context, ...
Cape Town, South Africa, November 9 (ots/PRNewswire) - - Technology Transfer Creates Sustainable Solution to Treat One of the World's Oldest and Deadliest Diseases During the annual meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD), The Lilly MDR-TB Partnership brought ...
Beijing, November 8 (ots/PRNewswire) - - Research Shows the New Test is Accurate, Simple to Run and Requires Minimal Resources Research demonstrating the potential of a special type of HPV test developed by QIAGEN with support from PATH -- a non-profit global health organization -- to reduce the incidence ...
Basel, Switzerland, November 7 (ots/PRNewswire) - - TOWARD Study, Presented at Major US Congress ACR, Confirms IL-6 Receptor Inhibition Plays a Key Role in the Treatment of RA The innovative new rheumatoid arthritis drug Actemra (tocilizumab) has been shown to significantly improve the signs and symptoms of rheumatoid arthritis (RA) in patients who failed to ...
NHMRC Clinical Trials Centre - The University of Sydney
Sydney, November 7 (ots/PRNewswire) - In the Lancet, on Tuesday November, 6th new results of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 2007 clinical trial have been published and presented on the same date at a press conference held during the AHA. - First lipid modifying agent shown to reduce the need for treatment of the leading ...
Shire Pharmaceuticals Group Plc
Philadelphia and Basingstoke, England, November 6 (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today announced the results of a Phase II study indicating that FOSRENOL can effectively reduce serum phosphate levels in chronic kidney disease (CKD) patients not on dialysis.(1) FOSRENOL is a non-calcium phosphate binder, indicated to treat ...
Lyon, France, November 6 (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today positive results in the development of a vaccine for the global prevention of dengue fever, one of the most widespread tropical diseases. The results are being presented today at the American Society of Tropical Medicine and Hygiene (ASTMH)'s ...
NHMRC Clinical Trials Centre - The University of Sydney
Sydney, November 6 (ots/PRNewswire) - - First Lipid Modifying Agent Shown to Reduce Risk of Leading Causes of Blindness and Deteriorating Vision in Patients With Type 2 Diabetes - Reduces Need for Laser Treatment in Patients With and Without Known Diabetic Retinopathy - Significantly Decreases Progression of Diabetic Eye Disease Fenofibrate is the ...
Orlando, Florida, November 5 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208, at the American Heart Association Scientific Meetings. The presentation titled "Oral ...
Shire Pharmaceuticals Group Plc
Basingstoke, England, November 5 (ots/PRNewswire) - - For global distribution excluding the US and Canada New data presented today at the 40th annual American Society of Nephrology (ASN) meeting and scientific exposition in San Francisco, CA, USA, show that epoetin delta - the only erythropoiesis-stimulating agent (ESA) produced in a human cell line - has ...
Amsterdam, November 5 (ots/PRNewswire) - - Highlights - Offer Price Expected to be in the Range of EUR12.50 to EUR16.00 Per Share - Offer Size Between EUR20 Million and EUR30 Million - Subscription Starts Today, 5 November 2007, and is Expected to End on 15 November 2007 - Trading on Eurolist by Euronext Amsterdam Expected to Commence on or About 16 November 2007 Avantium, a leading technology ...
Basel, Switzerland, November 5 (ots/PRNewswire) - -Low Haemoglobin Levels Associated With Increased Risk of Cardiovascular Disease and Death Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains haemoglobin ...
Tokyo and Indianapolis, November 4 (ots/PRNewswire) - - Duke Clinical Research Institute to lead multinational study with investigational compound; will include 10,000 medically managed patients with acute coronary syndrome A large Phase III clinical trial is anticipated to begin in the second quarter of 2008 to compare the effects of prasugrel, ...